OSMT
NASDAQOsmotica Pharmaceuticals plc
Latest news
25 items- NEWSOsmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales OutlookOsmotica Pharmaceuticals plc (NASDAQ:OSMT) will change its name to RVL Pharmaceuticals plc and start trading under the new ticker (NASDAQ:RVLP). The Company says that the rebranding reflects RVL's strategy to become a growth company in eye care and medical aesthetics. Upon FDA approval in 2020, the Company launched Upneeq (oxymetazoline hydrochloride ophthalmic solution), the first and only FDA-approved ophthalmic solution for acquired blepharoptosis (droopy eyelid(s)) or ptosis. Related: Osmotica Under Pressure On $35M Equity Raise To Pay Off Debt. The Company also posted Q4 FY21 net sales for Upneeq grew by approximately 41% sequentially, to $3.1 million. The cumulative unique phar
- SECOsmotica Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
- PROsmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in February 2022 -- -- Company to host video webcast at 8:30am ET on January 19, 2022 -- BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("OSMT" or the "Company"), a specialty pharmaceutical company, announced today that the Company has changed its name to RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL"). This rebranding reflects RVL's strategy to become a growth comp
- NEWSOsmotica Pharmaceuticals Says Q4 Net Sales For UNPEEQ Targeted To Range From $20M-$25MOsmotica Pharmaceuticals Says Q4 Net Sales For UNPEEQ Targeted To Range From $20M-$25M
- NEWSOsmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("OSMT" or the "Company"), a specialty pharmaceutical company, announced today that the Company has changed its name to RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL"). This rebranding reflects RVL's strategy to become a growth company in eye care and medical aesthetics, and, as part of this transformation, RVL has launched a new corporate website www.rvlpharma.com. Upon U.S. Food and Drug Administration ("FDA") approval in 2020, RVL launched UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only FDA-approved ophthalmic solution for the treatment of acquired blepharoptosis, more commonly known as droopy eyelid(s) or ptosi
- SECOsmotica Pharmaceuticals plc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)
- PRRVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper -- Bridgewater, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer and James "JD" Schaub, Chief Operating Officer, will host a video webcast to discuss recent UPNEEQ® trends, pending expansion into the medical aesthetics market and other general business updates. Dr. Jackie Yee is board-certified in Plastic and Reconstructive Surgery and speciali
- PROsmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows: Date:Wednesday, January 19, 2022Time:8:30 a.m. ETWebcast:https://experience.v-unite.com/#/aestheticrecorddemo/rvlinvestorday/room/welcome The webcast will be available thereafter via the Company's website at www.rvlpharma.com under the "Investor & News
- NEWS54 Biggest Movers From ThursdayGainers 22nd Century Group, Inc. (NASDAQ:XXII) surged 38.6% to settle at $3.05. The FDA authorized marketing of tobacco products that help reduce exposure to and consumption of nicotine for smokers who use them. The Oncology Institute, Inc. (NASDAQ:TOI) gained 38.5% to close at $10.44. Pasithea Therapeutics Corp. (NASDAQ:KTTA) shares climbed 36.7% to close at $2.01 on Thursday. Pasithea recently said it expanded its footprint with second Ketamine Therapy Clinic in the UK. Eliem Therapeutics, Inc. (NASDAQ:ELYM) gained 31% to settle at $14.19. Eliem Therapeutics, during November, reported a Q3 loss of $0.70 per share. REE Automotive Ltd. (NASDAQ:REE) jumped 26.6% to close at $5.04. Hita
- NEWS38 Stocks Moving In Thursday's Mid-Day SessionGainers Pasithea Therapeutics Corp. (NASDAQ:KTTA) jumped 37.3% to $2.0182. Pasithea recently said it expanded its footprint with second Ketamine Therapy Clinic in the UK. Allakos Inc. (NASDAQ:ALLK) jumped 27.3% to $10.88. Morgan Stanley maintained Allakos with an Equal-Weight and lowered the price target from $86 to $10. Allakos shares tumbled 90% on Wednesday after the company reported data from ENIGMA 2 Phase 3 study of lirentelimab in eosinophilic gastritis (EG) or eosinophilic duodenitis (EoD) and KRYPTOS Phase 2/3 study of lirentelimab in eosinophilic esophagitis (EoE). Society Pass Incorporated (NASDAQ:SOPA) shares jumped 22.8% to $20.03 after jumping over 53% on Wednesday. REE
- NEWS12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 27.89% to $1.88 during Thursday's pre-market session. The market value of their outstanding shares is at $41.1 million. Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 27.27% to $6.16. The company's market cap stands at $149.4 million. Genocea Biosciences (NASDAQ:GNCA) shares rose 13.46% to $1.18. The market value of their outstanding shares is at $67.7 million. Avalon Globocare (NASDAQ:AVCO) stock increased by 13.09% to $0.95. The company's market cap stands at $81.7 million. China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 11.43% to $0.64. The market value of their outstanding shares is at $
- NEWS18 Stocks Moving in Thursday's Pre-Market SessionGainers Pasithea Therapeutics Corp. (NASDAQ:KTTA) rose 26.5% to $1.86 in pre-market trading. Pasithea recently said it expanded its footprint with second Ketamine Therapy Clinic in the UK. Osmotica Pharmaceuticals plc (NASDAQ:OSMT) rose 21.7% to $1.29 in pre-market trading. HC Wainwright & Co. initiated coverage on Osmotica Pharmaceuticals with a Buy rating and announced a price target of $5. Allakos Inc. (NASDAQ:ALLK) rose 16.3% to $9.95 in pre-market trading. Allakos shares tumbled 90% on Wednesday after the company reported data from ENIGMA 2 Phase 3 study of lirentelimab in eosinophilic gastritis (EG) or eosinophilic duodenitis (EoD) and KRYPTOS Phase 2/3 study of lirentelimab in e
- NEWSHC Wainwright & Co. Initiates Coverage On Osmotica Pharmaceuticals with Buy Rating, Announces Price Target of $5HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Osmotica Pharmaceuticals (NASDAQ:OSMT) with a Buy rating and announces Price Target of $5.
- ANALYSTHC Wainwright & Co. initiated coverage on Osmotica Pharmaceuticals with a new price targetHC Wainwright & Co. initiated coverage of Osmotica Pharmaceuticals with a rating of Buy and set a new price target of $5.00
- NEWS4 Penny Stocks Insiders Are BuyingWhen insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Streamline Health Solutions The Trade: Streamline Health Solutions, Inc. (NASDAQ:STRM) Director Kenan Lucas acquired a total of 100000 shares at an average price of $1.50. To acquire these shares, it cost $150,000.00. What’s Happening: The company recently posted a narrower-than-expected quarterly loss. Wha
- INSIDERSEC Form 4: Schaub James bought $100,366 worth of Ordinary Shares (93,800 units at $1.07), increasing direct ownership by 30% to 405,900 units4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)
- PROsmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceBRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows: Date:Monday, January 10, 2022On Demand Time:7:00AM ETWebcast:https://journey.ct.events/view/b39a70c0-7058-4a1f-ba97-e18b13918fc7 The presentation will be webcast on-demand and available for 30 days thereafter using the link provided above and via the Company's website at www.osmotica.com under t
- SECSEC Form EFFECT filed by Osmotica Pharmaceuticals plcEFFECT - Osmotica Pharmaceuticals plc (0001739426) (Filer)
- SECSEC Form DEF 14A filed by Osmotica Pharmaceuticals plcDEF 14A - Osmotica Pharmaceuticals plc (0001739426) (Filer)
- SECOsmotica Pharmaceuticals plc filed SEC Form 8-K: Regulation FD Disclosure8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)
- SECSEC Form S-8 filed by Osmotica Pharmaceuticals plcS-8 - Osmotica Pharmaceuticals plc (0001739426) (Filer)
- SECOsmotica Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)
- SECSEC Form 10-Q filed by Osmotica Pharmaceuticals plc10-Q - Osmotica Pharmaceuticals plc (0001739426) (Filer)
- PROsmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business UpdateThird quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales Expansion of Upneeq launch continues with introduction of Direct Dispense program in eyecare and formation of Aesthetics business unit Sale of legacy business and capital raises streamlined business and strengthened balance sheet BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced business highlights and financial results for the three months ended September 30, 2021. "With the sale of our legacy business, we have accomplished our strategic goal of transformin
- PROsmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows: Date:Thursday, November 18, 2021On Demand Time:8:00AM GMT (3:00AM ET)Webcast:https://wsw.com/webcast/jeff201/osmt/1869930 The presentation will be webcast on-demand and available for 30 days thereafter using the link provided above and via the Company's website at www.osmotica.com under the "Investo
OSMT FAQ
7 questionsWhat does Osmotica Pharmaceuticals plc do?
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple...Where does OSMT stock trade?
Osmotica Pharmaceuticals plc (OSMT) is listed on NASDAQ.What sector and industry is OSMT in?
Osmotica Pharmaceuticals plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Osmotica Pharmaceuticals plc go public?
Osmotica Pharmaceuticals plc (OSMT) completed its IPO in 2018.What are analysts saying about OSMT?
Osmotica Pharmaceuticals plc has had 3 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $500.00 price target on 2021-12-23. Recent price targets range from $500.00 to $700.00.What companies are similar to OSMT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OSMT side-by-side with any of them on Quantisnow.How can I track OSMT on Quantisnow?
Quantisnow aggregates Osmotica Pharmaceuticals plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OSMT to receive live email and push alerts on every new disclosure.